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Salmonella
Typhimurium
DT104, Italy
To the Editor: The recent article
by Helms et al. described the distribu-
tion of Salmonella enterica serovar
Typhimurium definitive page type 104
(DT104) infections in 29 countries
from 1992 to 2001 (1). Results from
Italy were not presented because rou-
tine phage typing was not performed
before 2001. Since 2002, circulation
of  S. Typhimurium phage types has
been monitored by the laboratory-
based surveillance system Enter-net
Italia, which was coordinated by
Istituto Superiore di Sanità as part of
the European network for the surveil-
lance of foodborne infections (2).
From 2000 to 2004, S. Typhimurium
accounted for ≈40% of all human
Salmonella isolates each year. Since
2002,  ≈20% of the S. Typhimurium
isolates were identified as DT104, and
all had a pentavalent resistance pattern
(resistance to ampicillin, chloram-
phenicol, streptomycin, sulfonamides,
and tetracycline) (3). Although the
results reported by Helms et al. (1)
refer to a different period
(1992–2001), the Italian data are simi-
lar to those from many other countries
in northern and western Europe.
According to the Colindale
scheme for phage typing ([4] and L.R.
Ward, pers. comm.), numerous distin-
guishable DT104 subtypes can be
identified as DT104 A, B, C, H, and
L. Most (90%) S. Typhimurium
DT104 strains isolated during the last
2 years belonged to subtype DT104L.
Emergence of phage subtype
DT104A was identified in June 2004
during an outbreak of salmonellosis in
Rome. This subtype had never been
previously identified in Italy. All
DT104A isolates were susceptible to
the Enter-net panel of antimicrobial
drugs (2), a feature unusual for S.
Typhimurium (5). A total of 63 cases
were confirmed; 61 were from Rome,
and 2 were from a neighboring region.
All isolates had similar pulsed-field
gel electrophoretic profiles when ana-
lyzed with the Salm-gene protocol
(6). Since the outbreak, 1 additional
human isolate of DT104A was identi-
fied from a resident of the same
neighboring region. This isolate was
also susceptible to the panel of antimi-
crobial drugs. A fermented pork sala-
mi was epidemiologically implicated
as the vehicle of infection. No micro-
biologic evidence was found because
no food samples were available when
the outbreak was recognized.
The incidence of DT104 in Italy
has remained stable from 2002
through 2004. However, emergence
of subtype DT104A during a recent
outbreak highlights the need for sub-
typing in identifying communitywide
outbreaks and in monitoring changing
subtype patterns.
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Echovirus 13
Aseptic Meningitis,
Brazil 
To the Editor: Human entero-
viruses (polioviruses, coxsackievirus
A, coxsackievirus B, echoviruses,
enterovirus 71, and newer recognized
serotypes) belong to the Picorna-
viridae family, Enterovirus genus (1).
They are common viral agents associ-
ated with a diversity of clinical mani-
festations, including respiratory ill-
ness; nonspecific rashes; hand, foot,
and mouth disease; myocarditis; acute
hemorrhagic conjunctivitis; and cen-
tral nervous system (CNS) syndromes
(2). Acute viral infections of the CNS
are the source of a group of globally
distributed diseases, which affect the
population in a sporadic, endemic, or
epidemic way. These infections cause
a number of illnesses, particularly in
children, and may result in serious
sequelae; in severe cases, they can be
fatal (3). Meningitis, encephalitis,
acute flaccid paralysis (poliomyelitis),
mononeuritis, polyneuritis, and Reye
syndrome constitute most of the ill-
nesses (4). Nonpolio enteroviruses are
responsible for >80% of viral menin-
gitis cases in which the etiologic agent
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is identified (2). Several of the 28 cur-
rently recognized serotypes of
echovirus are found in association
with these infections (3).
We describe an outbreak of aseptic
meningitis that occurred in southern
Brazil in 2003 with echovirus 13
(E13) virus as the etiologic agent.
This is the first meningitis outbreak
due to E13 reported in the country.
From March to April 2003, 17
children and young adults from
Horizontina City (population
16,800), Rio Grande do Sul State,
southern Brazil, with symptoms of
meningitis, sought medical attention
at the local hospital. Seven of these
case-patients were linked to each
other either by school or domiciliary
contact. Lumbar puncture showed
clear cerebrospinal fluid (CSF),
which suggests a viral cause. The fol-
lowing symptoms were associated
with patients: fever (92%), headache
(84%), vomiting (79%), diarrhea,
stiff neck, and fatigue (7.69% each).
Patients’ ages ranged from 1 to 19
years of age, with the age peak inci-
dence in children 5–9 years of age
(46%). Fifty-eight percent of patients
were male. All patients recovered,
and no sequelae or deaths were iden-
tified. The pattern of meningitis asso-
ciated with E13 in this outbreak was
clinically similar to those observed in
aseptic meningitis due to other
enteroviruses in previous outbreaks.
For diagnostic purposes, 12 CSF
and 8 fecal specimens were collected
from the 17 patients with clinically
suspected viral meningitis. For viral
diagnosis, RD and HEp2 cells were
injected with 0.2 mL of each clinical
specimen (clarified fecal specimens
and CSF) and examined daily for at
least 7 days postinoculation. Entero-
virus characteristic cytopathic effect
was observed in 6 (50%) of 12 CSF
samples and in 5 (62.5%) of 8 fecal
samples. All isolates were typed as
echovirus 13 by a reverse transcrip-
tion–PCR and nucleotide sequencing
of a portion of the VP1 gene (5).
Before 2000, echovirus 13 was
considered a rare serotype of
enterovirus (6) and had never been
reported in association with outbreaks
(7). In the United States, before 2001,
this enterovirus accounted for only 65
of the 45,000 reported enteroviral iso-
lates (6). However, the incidence of
E13 is increasing; several meningitis
outbreaks have been recently reported
in England, Germany, Belgium,
Spain, France, Israel, and Japan (8).
In spite of the temporal clustering
and close contact of 7 patients, the
causes of the outbreak were not com-
pletely defined and remain specula-
tive. The sudden emergence of E13 as
a prominent enterovirus associated
with viral meningitis in many coun-
tries, including Brazil, demonstrates
the potential of enteroviruses to cir-
culate widely and to unpredictably
cause diseases, which underscores
the continued need for enterovirus
surveillance.
Although this specific outbreak
was restricted both geographically
and in terms of magnitude (only 17
cases), E13 seemed to be widely dis-
tributed in Brazil and has been detect-
ed in fecal specimens obtained from
patients with acute flaccid paralysis
since 1998 (C. Blal, unpub. data).
Epidemiologic surveillance plays a
crucial role in understanding the
changing patterns of enterovirus
infection and disease associations.
Such knowledge may help in the con-
trol of diseases (9,10). Although iden-
tifying the enterovirus serotype does
not contribute substantially to patient
management, establishing the domi-
nant virus each year or in each out-
break is essential for epidemiologic
purposes.
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Nonsteroidal
Antiinflammatory
Drugs and Group A
Streptococcal
Infection
To the Editor: Factor et al.
recently reported the results of a pop-
ulation-based, case-control study
regarding risk factors for pediatric
invasive group A streptococcal
(GAS) infection (1), noting that the
“new” use of nonsteroidal antiinflam-
matory drugs (NSAIDs), defined as
NSAID use <2 weeks before diagno-
sis, was associated with invasive
GAS infection, whereas self-defined
“regular” NSAID use was not. The
control population consisted of non-
hospitalized, age-matched children
contacted by telephone (1). Although
we endorse the authors’ conclusion
that, “…the measurements of new use
and regular use [of NSAIDs] are too
crude to clearly identify their role as
a risk factor,” a more detailed discus-
sion of their findings and conclusions
is warranted.
Because of their antiinflammatory
effects, NSAIDs have been suspected
of suppressing host immunity during
infection, particularly GAS infection
(2). However, determining a causal
association between NSAID use and
infectious diseases has been problem-
atic, especially when using retrospec-
tive studies (3). The results of such
observational studies often suffer from
protopathic bias, in which drugs are
applied to treat symptoms that are
actually early manifestations of the
outcome of interest (4). Consequently,
rather than being a direct determinant
(i.e., causative risk factor) for invasive
GAS infection, NSAID use could
mark the onset of disease symptoms
(fever, localized pain, and inflamma-
tion). Therefore, because of protopath-
ic bias, the study by Factor et al. had a
substantial chance of identifying an
association between NSAID use and
invasive GAS infection a priori.
Neither the fact that patients in the
study by Factor et al. received
NSAIDs any time during the 2 weeks
before the diagnosis of invasive GAS
infection nor the finding that nonhos-
pitalized children (controls) were
unlikely to have received NSAIDs in
the 2 weeks before their interview
should be surprising. Amore informa-
tive case-control study would have
matched case-patients with similar-
aged children who had febrile infec-
tions not caused by GAS infection;
both groups of children would have
been equally likely to have received
analgesic and antipyretic medications.
Furthermore, population-based data
suggest that most patients with inva-
sive GAS infection are hospitalized
(5), so hospital-based controls, rather
than population controls, might have
provided a more appropriate compari-
son group.
Prospective studies have failed to
define a causal link between NSAIDs
and invasive GAS infections (3),
though such studies were not specifi-
cally designed to investigate this rela-
tionship. To best test the hypothesis
that NSAIDs increase the risk for
invasive GAS infection, a random-
ized, prospective trial should be done.
Such a trial is unlikely to take place,
however, because of questionable
ethics and because the sample neces-
sary to detect a significant difference
would be prohibitively large.
Although NSAIDs may neither
alter the risk of developing an invasive
GAS infection nor accelerate an estab-
lished infection, these drugs can molli-
fy the signs and symptoms of strepto-
coccal infection, possibly delaying
appropriate management and treat-
ment (3). However, the potential
adverse consequences of suppressing
clinical indicators of disease severity
(e.g., fever, pain, and inflammation)
with NSAIDs apply to myriad infec-
tious and inflammatory conditions, not
just invasive streptococcal disease.
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